Loading clinical trials...
Loading clinical trials...
A Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of Cediranib 45mg Versus Placebo Following 12 Weeks of Treatment in Patients With Metastatic or Recurrent Renal Cell Carcinoma Who Have Had no Previous Anti-VEGF Therapy.
Conditions
Interventions
Cediranib
Cediranib Placebo
Locations
8
Netherlands
Research Site
Groningen, Netherlands
Research Site
Leiden, Netherlands
Research Site
Nijmegen, Netherlands
Research Site
Birmingham, United Kingdom
Research Site
London, United Kingdom
Research Site
Manchester, United Kingdom
Start Date
January 1, 2007
Primary Completion Date
March 1, 2008
Completion Date
October 1, 2016
Last Updated
February 2, 2017
NCT07485114
NCT06391099
NCT05738694
NCT07227402
NCT06349642
NCT07300241
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions